Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Sjogren syndrome xerostomia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Sjogren syndrome xerostomia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Sjogren syndrome xerostomia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Sialorrhea Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Sialorrhea Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Sialorrhea indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Sialolithiasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Sialolithiasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Sialolithiasis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Sialadenitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Sialadenitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Sialadenitis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Radiation-induced xerostomia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Radiation-induced xerostomia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Radiation-induced xerostomia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Ameloblastic carcinoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Ameloblastic carcinoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Ameloblastic carcinoma strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Salivary gland hypofunction Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Salivary gland hypofunction Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Salivary gland hypofunction strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Read →
Odontogenic myxoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Odontogenic myxoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
Explore the 2026 Odontogenic myxoma indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Read →
Clear cell odontogenic carcinoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Clear cell odontogenic carcinoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Clear cell odontogenic carcinoma strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Micron Biomedical Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
Latest Hotspot
8 min read
Micron Biomedical Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
5 August 2026
Micron Biomedical BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.
Read →
Adenomatoid odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Adenomatoid odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Adenomatoid odontogenic tumor strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Read →
Calcifying epithelial odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
Latest Hotspot
10 min read
Calcifying epithelial odontogenic tumor Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
5 August 2026
2026 Calcifying epithelial odontogenic tumor strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap.
Read →